MiNA Therapeutics
Peter was appointed Chief Business Officer in 2020 after serving several years as a Non Executive Director. Peter brings three decades of experience in the global pharmaceutical space. Peter has held multiple leadership roles in biopharmaceuticals, most recently as Chief Executive Officer of Sosei Heptares (TSE:4565) and Syngene International (NSE:SYNGENE). Prior to this Peter held a number of roles over 23 years at GlaxoSmithKline including Head of Global Marketing and Senior VP of Commercial Development for GSK’s International Region. Peter is a Non Executive Director of Mereo BioPharma (NASDAQ:MREO) and Indivior (LSE:INDV).
This person is not in any offices
MiNA Therapeutics
Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases.